Showing 1 - 2 results of 2 for search 'Hjalmar, V', query time: 0.02s
Refine Results
-
1
Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). by Lundin, J, Kimby, E, Björkholm, M, Broliden, P, Celsing, F, Hjalmar, V, Möllgård, L, Rebello, P, Hale, G, Waldmann, H, Mellstedt, H, Osterborg, A
Published 2002Journal article -
2
Phase II study of subcutaneous alemtuzumab (Campath-1H) therapy of patients with previously untreated chronic lymphocytic leukemia (CLL). by Lundin, J, Kimby, E, Bjorkholm, M, Celsing, F, Hale, G, Hjalmar, V, Merup, M, Petrescu, A, Tullgren, O, Waldmann, H, Mellstedt, H, Osterborg, A
Published 2001Journal article